Anya Biopharm (ROCO:7776) Change In Receivables: NT$-0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7776 Anya Biopharm Inc ROCO:7776
20 GF Score
Price NT$32.00
! 4 Warning Signs
View Full Analysis

What is Anya Biopharm Change In Receivables?

Anya Biopharm ROCO:7776 20 Change In Receivables is NT$-0.00 Mil as of Jun. 2026. GuruFocus rates ROCO:7776 with a GF Score™ of 20/100. The stock has 4 warning signs investors should review.

Anya Biopharm's change in receivables for the quarter that ended in Jun. 2026 was NT$11.76 Mil. It means Anya Biopharm's Accounts Receivable declined by NT$11.76 Mil from Dec. 2025 to Jun. 2026 .

Anya Biopharm's change in receivables for the fiscal year that ended in Dec. 2025 was NT$-11.72 Mil. It means Anya Biopharm's Accounts Receivable increased by NT$11.72 Mil from Dec. 2024 to Dec. 2025 .

Anya Biopharm's Accounts Receivable for the quarter that ended in Jun. 2026 was NT$0.12 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Anya Biopharm's Days Sales Outstanding for the six months ended in Jun. 2026 was 30.83.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Anya Biopharm's liquidation value for the six months ended in Jun. 2026 was NT$309.81 Mil.

Anya Biopharm  (ROCO:7776) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Anya Biopharm's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.123/0.728*91
=30.83

2. In Ben Graham's calculation of liquidation value, Anya Biopharm's accounts receivable are only considered to be worth 75% of book value:

Anya Biopharm's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=317.844-8.126+0.75 * 0.123+0.5 * 0
=309.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anya Biopharm Change In Receivables Related Terms

Anya Biopharm Change In Receivables Historical Data

* Premium members only.

The historical data trend for Anya Biopharm's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anya Biopharm Change In Receivables Chart

Anya Biopharm Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Change In Receivables
-0.17 0.39 0.01 -11.72

Anya Biopharm Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Change In Receivables Get a 7-Day Free Trial -0.13 0.13 0.04 -11.76 11.76
ROCO:7776
20GF Score
Anya Biopharm Inc ROCO:7776
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anya Biopharm Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of NT$-0.00 Mil mean?
Anya Biopharm (ROCO:7776) has a Change In Receivables of NT$-0.00 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Anya Biopharm and its competitors.
Is Anya Biopharm's Change In Receivables too high?
Anya Biopharm's current Change In Receivables is NT$-0.00 Mil. Overall, Anya Biopharm has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Anya Biopharm's Change In Receivables compare to VRTX and REGN?
Anya Biopharm's Change In Receivables of NT$-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Anya Biopharm and its competitors. Anya Biopharm's current Change In Receivables is NT$-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anya Biopharm stock overvalued right now?
Anya Biopharm (ROCO:7776) has a current Change In Receivables of NT$-0.00 Mil. The current Change In Receivables is NT$-0.00 Mil. Anya Biopharm's overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Anya Biopharm (ROCO:7776), the current Change In Receivables is NT$-0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anya Biopharm Business Description

Address No. 3-2, Yuanqu Street, 4th Floor, Nangang, Taipei, TWN, 115603
Anya Biopharm Inc is a pharmaceutical company engaged in the Oral Delivery of Peptides. Its patented technology platform Mira/Je is a flexible solution easy to adapt to a large variety of peptides.
20GF Score

Get the complete analysis for ROCO:7776

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.00
Price